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Suspension bead array (SBA)
Parallel reaction monitoring (PRM)
A B S T R A C T
Detailed knowledge of protein changes in cerebrospinal fluid (CSF) across healthy and diseased individuals
would provide a better understanding of the onset and progression of neurodegenerative disorders.
In this study, we selected 20 brain-enriched proteins previously identified in CSF by antibody suspension bead
arrays (SBA) to be potentially biomarkers for Alzheimer's disease (AD) and verified these using an orthogonal
approach. We examined the same set of 94 CSF samples from patients affected by AD (including preclinical and
prodromal), mild cognitive impairment (MCI), non-AD dementia and healthy individuals, which had previously
been analyzed by SBA. Twenty-eight parallel reaction monitoring (PRM) assays were developed and 13 of them
could be validated for protein quantification.
Antibody profiles were verified by PRM. For seven proteins, the antibody profiles were highly correlated with
the PRM results (r > 0.7) and GAP43, VCAM1 and PSAP were identified as potential markers of preclinical AD.
In conclusion, we demonstrate the usefulness of targeted mass spectrometry as a tool for the orthogonal ver-
ification of antibody profiling data, suggesting that these complementary methods can be successfully applied for
comprehensive exploration of CSF protein levels in neurodegenerative disorders.
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Neurodegenerative disorders such as Alzheimer's disease (AD),
Parkinson's disease (PD), dementia with Lewy bodies (DLB) and fron-
totemporal dementia (FTD) predominantly affects older individuals.
Although the underlying mechanisms are unclear, disease onset is most
likely due to a concurrency of events including age related decline of
biochemical processes together with other disease-promoting factors
[1–4]. AD is the most common type of dementia in older adults
(> 65 years), accounting for 60–70% of all dementia cases [5]. It is
characterized by neuronal degeneration throughout the brain causing
symptoms such as memory loss, difficulties in thinking, understanding
and judging, personality changes, hallucinations and ultimately death
[WHO, 2017].
Cerebrospinal fluid (CSF) covers an important role in central ner-
vous system as mechanical protection for the brain but also in the
regulation of brain interstitial fluid homeostasis and metabolism [6].
The protein concentration in CSF may change as a result of neuronal
damage, altered neuronal functions or CSF flow rate. It therefore re-
presents an exquisite source of information about the status of the
central nervous system in physiological and pathological conditions
[5,7]. In the past years, several efforts to build a comprehensive data-
base of the human CSF proteome in healthy [8,9] and diseased [10]
individuals have been initiated.
Although mass spectrometry (MS) is regarded as the workhorse of
proteomic studies, antibody arrays, such as single binder immunoassays
or suspension bead arrays (SBA) [11] have shown to be successful and
advantageous for protein profiling of CSF samples. They have been used
to discover candidate biomarkers in neurodegenerative disorders such
as AD, PD, DLB [12] and multiple sclerosis [13,14].SBA assays allow for
both high sample throughput and high analyte multiplexing, re-
presenting a very powerful approach for screening large cohorts of
samples. However, the SBA technology has mainly been applied as an
exploratory screening tool and subsequent evaluation of potential off-
target interactions has, as for all multiplex protein profiling assays,
been necessary.
Parallel reaction monitoring (PRM) is now emerging as an alter-
native to SRM [15–17] in the analysis of CSF and other bodily fluids
[18,19].PRM is implemented on a quadrupole mass filter in line with a
high resolution and accurate mass analyzer (Orbitrap), allowing for the
analysis of all potential product ions of a precursor. For this workflow,
less laborious method development is required compared to SRM, since
product ions are not selected a priori [20,21], therefore making PRM an
ideal targeted approach for qualification and verification of protein
profiles.
The aim of our study was to investigate the use of PRM for the
verification of SBA protein profiles in CSF. We selected 20 brain-en-
riched proteins previously profiled found to be interesting in the con-
text of AD by Remnestål et al. [12] and we proceeded with development
of PRM methods for their quantification in CSF. The assays implement a
semi-automated approach for sample preparation and “single point
calibration” quantification using QPrEST™ heavy labeled protein frag-
ments as internal standards (Fig. 1) [22]. Despite a general agreement
that assays in preclinical research do not need to follow the same
standards as assays used in clinical applications, it is increasingly evi-
dent that the success of biomarker discovery depends on validated
analytical assays [21,23,24]. We applied the PRM assays developed to
the same cohort of 94 lumbar CSF samples previously analyzed using
the antibody-based SBA with the aim of performing an orthogonal
verification of protein profiles showing potential clinical interest.
2. Experimental section
2.1. Chemicals and reagents
Acetonitrile (ACN) HPLC Gradient grade was purchased from Fisher
Chemical (Waltham, MA USA). Formic acid (FA) (LOT# 174566) was
from Fisher Chemical (Waltham, MA USA). Ammonium bicarbonate
(LOT# BCBN6056V, ≥99% purity), DL-dithiothreitol (DTT) (LOT#
BCBR9439V, ≥99.5% purity), iodoacetamide (IAA) (LOT#
SLBD7510V, ≥99% purity) and sodium deoxycholate (SDC) (LOT#
086K0045V, ≥97% purity) were purchased from Sigma Aldrich (St.
Louis, MO, USA). Trypsin/Lys-C Mix, Mass Spec Grade (20 μg) was
obtained from Promega (Madison, WI, USA). Milli-Q water purification
system (Millipore, Bedford, MA, USA) was used to obtain ultrapure
water. Heavy labeled QPrESTs used as internal standards were obtained
from the Human Protein Atlas and produced as described previously
[22] (Table 1). The protein concentration of each QPrEST had pre-
viously been determined with the bicinchoninic acid (BCA) assay. The
gene name displayed will be used to denote the QPrEST and the cor-
responding endogenous target in this report.
2.2. CSF samples
The cohort analyzed in this study consisted of CSF collected by
lumbar puncture at the L3/L4 interspace from 94 living individuals
with AD (43), prodromal AD (2), preclinical AD (14), non-AD dementia
(2), non-AD mild cognitive impairment (MCI) (10) and healthy controls
(23) at Sahlgrenska University Hospital in Gothenburg, Sweden. The
study was approved by the regional ethics committee and all patients
had given their informed consents. The diagnostic criteria applied was a
combination of clinical diagnosis (cognitively normal, mild cognitive
impairment or dementia) and the CSF biomarker profile of tau (total
tau, t-tau and phospho-tau, p-tau) and Aβ1–42 [25]. Patients diagnosed
with prodromal AD (early-stage AD) had decreased CSF Aβ1–42 and
increased levels of either t-tau or p-tau, deteriorating memory but no
functional impairments. Patients diagnosed with Preclinical AD had
abnormally decreased CSF levels of Aβ1–42. Control samples were col-
lected from volunteers asymptomatic of dementia (cognitively normal)
and CSF levels of tau and Aβ1–42 within the normal ranges [12]. Table 2
shows the demographics of the cohort. After sampling, CSF was cen-
trifuged at 2000 x g for 10min at RT and stored at −80 °C. Prior to this
study, the samples had undergone two freeze/thaw cycles. The samples
were thawed on ice and aliquoted into a 96-well plate in a randomized
layout. The plate was stored at −80 °C until analysis.
Commercial lumbar CSF pooled from healthy donors (LOT#
W53211, Lee Biosolutions, Maryland Heights, MO, USA), was used for
method development and parts of the method validation. Two pools of
CSF, one with high and one with low levels of the proteins of interest,
assembled from the clinical samples were also used for assays optimi-
zation and validation, where high and low protein levels estimations
were based on the previous semi-quantitative measurements by SBA
[12]. 10 μL from 26 samples showing the highest or lowest levels for
most of the 20 targets were pooled to generate the “high” and the “low”
pool, respectively.
2.3. Sample preparation for MS analysis
All 20 proteins, besides NBEA, were detected previously by MS
analysis in CSF according to the PeptideAtlas database [26] with nor-
malized peptide spectrum matches (PSMs) ranging from 0.3 (NEFM) to
1141 (SERPINA1).
2.3.1. Digestion
Samples required for method development were prepared from
10 μL of starting material in Eppendorf LoBind tubes (Eppendorf,
Hauppauge, NY, USA). Samples were prepared in duplicates (shotgun-
MS analysis/digestion test, spike-in determination of QPrESTs) or tri-
plicates (peptide clean-up evaluation). Samples for comparison of
starting material volume (10 vs. 20 μL) were prepared in triplicates and
samples required for method validation were prepared in triplicate
unless otherwise stated from 20 μL of starting material in low binding
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96-well plates (KingFisher, Thermo Fisher Scientific). Patient samples
(20 μL CSF) were aliquoted to low binding 96-well plates using the
CyBio-SELMA system and reagents dispensed using an electronic
stepper pipette (Eppendorf Multipipette Stream).
CSF samples were diluted 1:10 with ammonium bicarbonate
(200mM) and SDC (0.25%) and QPrEST internal standards were spiked
into each sample followed by reduction (DTT 2.5mM, 56 °C, 30min)
and alkylation (IAA 4.0mM, room temperature (RT) in darkness,
30 min). The reaction was quenched with DTT at 2.5 mM and the vo-
lume adjusted to 95 μL with SDC (0.25%). Trypsin/Lys-C mix was
added to the sample at a ratio of 1:25 to total protein and incubated at
37 °C overnight (ON). Incubation times of 10, 30, 60 and 180min were
compared to ON when selecting optimal digestion time. The sample was
then acidified with 5 μl of 10% trifluoroacetic acid (TFA) and 5 μL of 5%
acetic acid and incubated for 30min at RT. By centrifugation, (1575 xg
30min for samples in plates; 25,200 xg, 15min for samples in tubes)
the supernatant was separated from the precipitated SDC, collected and
cleaned by solid phase extraction (SPE) as described below.
Appropriate QPrESTs spike-in concentrations were determined
using a 5-point dilution series of QPrESTs spiked into constant level of
commercial CSF. The linearity was determined using a 12-point dilution
curve of the high pool in a blank matrix (artificial CSF), spiked with a
constant concentration of QPrESTs. Artificial CSF was prepared with a
mixture of electrolytes as described in Cold Spring Harbor Protocols,
2011 [27]. We supplemented the solution of electrolytes with rabbit
immunoglobulin G (Bethyl Laboratories, P120–301) and bovine serum
albumin (Sigma Aldrich, SLBR5497V, LOT# STBF7163V) to obtain a
total protein concentration of 0.8mg/ml. Briefly, the solution con-
tained: 119mM NaCl, 26mM NaHCO3, 2.5 mM KCl, 1mM NaH2PO4,
1.3 mM MgCl2, 10mM glucose and 2.5mM CaCl2, 0.67mg/mL BSA
and 0.13mg/mL rabbit IgG. The solution was stored at 4 °C up to one
week.
2.3.2. Clean-up strategies
ZipTip C18 tips with 0.6 μL bed of chromatography media
(Millipore, Billerica, MA, USA) were used for the clean-up of the tryptic
peptides in the first phases of development (shotgun-MS/digestion test,
volume comparison). Selected SPE cartridges were evaluated for the
clean-up of the tryptic peptides and compared to the performance of the
C18 ZipTip. Tested SPE sorbents were mixed-mode strong cation ex-
change (MCX), mixed-mode strong and weak anion exchange (MAX and
WAX, respectively) and hydrophilic-lipophilic balance (HLB) and
HLBPrime (Oasis, 1 cc, Waters). Furthermore, a C18 cartridge (Sep-Pak,
130mg sorbent, Waters) was also evaluated in comparison. The com-
mercial CSF was used in all procedures. To avoid preparation artefacts
not related to the SPE procedure, digests were pooled, thoroughly
vortexed, and then divided into three aliquots for replicate comparison
before SPE treatment. Protocols for each sorbent are found in
Supplementary Excel Table 1. Three separate protocols were im-
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Fig. 1. Study design outline. 20 brain-enriched proteins previously profiled by antibody suspension bead arrays (SBA) were selected for a profile verification by
targeted mass spectrometry. Parallel reaction monitoring (PRM) assays were developed for 17 out of 20 targets using heavy labeled protein fragments (QPrESTs)
covering a region of the proteins of interest. Samples were spiked with QPrESTs for each target protein, and processed in a semi-automated protocol which exploit
automated pipetting and on-plate clean up procedures. Previously obtained SBA results (MFI values) were compared with peptide ratio obtained by scheduled PRM.
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(HLBb) and neutral sample (HLBg), as suggested by the provider [28]
and described in Supplementary Excel Table 1.
Oasis® HLB was selected for method validation and cohort samples.
In order to prepare the samples in a high-throughput fashion we chose
the Oasis® HLB 96-well μElution plate format with 2mg sorbent and
30 μm particle size (Waters, Milford, MA, USA). Solutions were drawn
through the microcolumns by the use of a vacuum pump (KNF
Laboport) and the Oasis® 96-well plate vacuum manifold kit (Waters,
Milford, MA, USA). Columns were conditioned with 0.2 mL methanol
and equilibrated with 0.2 mL Milli-Q. The samples were loaded (ap-
prox. 97 μL) and the flow through was discarded. The columns were
washed with 0.2mL 5% methanol and the samples were then eluted
with 0.1 ml 2% FA in 60% ACN+40% methanol. After elution, the
solvent was evaporated (SpeedVac Concentrator Savant SPD111V and
UVS400A, Thermo Fisher Scientific). Peptides were stored as dried
pellets at −20 °C and re-suspended with buffer A (3% ACN+0.1% FA)
before injection. Injection volume was 20% of the total resuspension
volume (2 of 10 μL or 5 of 25 μL).
2.4. Instrumental analysis
MS analysis was performed on a Q-Exactive HF Hybrid Quadrupole-
Orbitrap mass spectrometer (Thermo Fisher Scientific) coupled to a
Dionex Ultimate 3000 RSLC nanosystem (Thermo Fisher Scientific) for
reversed phase chromatography. Samples were automatically injected
onto a C18 trap column followed by a C18 EASY-Spray analytical
column. The system was controlled with the Xcalibur software (Thermo
Fisher Scientific).
Shotgun analysis for peptide identification was performed using a
C18 EASY-Spray analytical column, dimensions 50 cm×75 μm ID,
particle size 2 μm (Thermo Fisher Scientific). Chromatographic se-
parations were achieved with a multistep gradient of buffer B (95%
ACN+0.1% FA) starting at 3% for 5min: 3% to 8% for 3min, 8% to
30% for 42min, 30% to 43% for 5min and 43% to 99% for 2min. B was
then held at 99% for 5min before decreased to 3% to equilibrate the
system. Total run time was 74min with a flow rate of 250 nL/min.
Electrospray ionization (ESI) source settings were positive ionization
mode, spray voltage (kV) 3.50, capillary temperature (°C) 320, sheath
gas flow rate 7, aux gas flow rate 2 and S-lens radio frequency (RF) level
60. The instrument was operating in data-dependent acquisition mode
with a full MS1 scan in the range m/z 400–1600 with 60,000 resolving
power at m/z 200, automatic gain control (AGC) target 3e6 and max-
imum ion injection time (IT) 100ms. The five most abundant precursors
were selected for MS2 and fragmented with normalized collision energy
(NCE) 30. Single and unassigned charge states were excluded.
Precursors selected for MS2 were put on a dynamic exclusion for 60 s.
MS2 was performed with 30,000 resolving power at m/z 200, AGC
target 1e5 and maximum IT 100ms.
For PRM assays, peptide separation was optimized on a 25 cm C18
EASY-Spray analytical column (dimensions 25 cm×75 μm ID, particle
size 2 μm, Thermo Fisher Scientific) using a multistep gradient of B
starting at 3% for 5min: 3% to 32% for 35min, 32% to 47% for 3min
and 47% to 99% for 2min. B was then held at 99% for 7min and then
decreased to 3% to equilibrate the system. A flow rate of 400 nL/min
was used and the total run time was 58min. ESI source settings were
maintained as described above. The PRM assays consisted of one full
MS1 event followed by up to 25 targeted MS2 events. The full MS1 scan
covered the mass range m/z 150–2000 with 60,000 resolving power at
m/z 200, AGC target value 2e5 and maximum IT 55ms. For MS2,
precursors scheduled with an elution window of approximately 5min
(Supplementary Table 2) were fragmented with NCE 27. Scan settings
were 30,000 resolving power at m/z 200, AGC target 1e6, maximum IT
250ms and precursor isolation window was set to 2.0 Th. PRM para-
meters were optimized for up to eight points across the curve. For
method development and optimization, PRM methods were run in un-
scheduled mode.
2.5. Suspension bead arrays (SBA)
The data generated by the SBA technology was previously reported
by Remnestål et al. [12].
2.6. Data analysis
For peptide and protein identification in the shotgun-MS analysis,
raw data was imported into MaxQuant version 1.5.3.30 [29]. Searches
were performed with MaxQuant's search engine Andromeda against the
human protein database from Uniprot (accessed on 03/17/2016, Ca-
nonical and Isoforms, 20,198 hits) customized with the QPrEST se-
quences. The following settings were used: trypsin and Lys-C cleavage
after Arg and Lys residues but not when followed by Pro, fixed mod-
ifications: carbamidomethyl (Cys), variable modifications: oxidation of
methionine residues, acetyl-group on the N-terminal, Arg-10, Lys-8,
maximum missed cleavages: 5.
Skyline version 3.7.0.10940 [30] was used for PRM data analysis
and peptide quantification. Selected peptides were verified to be unique
to the human protein of interest. Identical heavy and light transitions
and retention times confirmed peptide identity. A minimum of three
transitions was required for reliable detection. All peaks were manually
inspected to confirm correct detection and peak boundaries. Peak in-
tegration and calculation of the ratios between light endogenous and
the heavy-labeled peptide (L/H) were done in Skyline and result reports
exported from the software. Where applicable, an estimation of the
endogenous protein concentration was made based on the L/H peptide
ratio multiplied with the spiked-in QPrEST concentration for the cor-
responding protein (“single point calibration”).
Linearity was evaluated by regression analysis using the three re-
plicates for each point of dilution. The line of best fit with a 95%
confidence interval was represented and used to calculate limits of
detection and quantification (LOD and LOQ, respectively). LOD and
LOQ were estimated as 3.3Sa/b and 10Sa/b, respectively, where Sa is
the SD of the y-intercepts and b is the slope of the dilution curves.
Four replicates of the commercial CSF were prepared on three dif-
ferent days to evaluate the intra-and inter-day variation of the sample
preparation procedure for each peptide. The intra-day variation was
defined as the mean CV (%) calculated from the CVs (%) obtained from
the experiments that were performed on the same day. The inter-day
variation was defined by two methods; 1) replicate 1 was compared on
all days, replicate 2 was compared on all days, etc., as suggested in [33]
and 2) the CV (%) calculated from the mean ratios from the intra-day
replicates across the different days.
The accuracy was evaluated from all 12 replicates prepared (mean
concentration ± SD) and defined as the closeness (expressed as %) to
the mean concentration for one day of repeated experiments. Carry-
over (expressed as %) was estimated by blank solvent injections after
sample injection.
Peptide levels obtained by PRM were compared between clinical
subgroups by pairwise Wilcoxon rank sum tests. False discovery rate
Table 2
Cohort demographics.
Diagnosis N Age median
(range)
Gender F/M
AD 43 81 (53–102) 28/15
Prodromal AD 2 90 (88–92) 2/0
Preclinical AD 14 85 (73–96) 10/4
Non-AD dementia 2 84 (82–86) 0/2
Non-AD mild cognitive impairment
(MCI)
10 84.5 (56–93) 8/2
Healthy 23 79 (44–91) 12/11
Total 94
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was adjusted using the Bonferroni method. Samples measuring below
LOQ (if available) and small patient groups (n=2) were excluded.
Pearson's correlation coefficient (Pearson's r) was calculated to evaluate
the concordance in the protein levels obtained by PRM (L/H peptide
ratio) and the SBA technology (MFI values) and the strength of corre-
lation evaluated based on elsewhere suggested strategies [31].
Plots were visualized and statistical analyses performed using R
(RStudio version 1.0.153) [32] .
3. Results
In this study, we have developed PRM assays for proteins in CSF
with the aim to verify previously identified associations to AD as ob-
served with antibody suspension bead arrays. In total, assay develop-
ment for 20 brain-enriched proteins (Table 1) were performed and
applied to 94 human CSF samples.
3.1. Development and validation of PRM assays
3.1.1. Selection of tryptic peptides and methods development
The initial list of targets of interest in the contest of Alzheimer's
disease included 20 proteins. QPrESTs for each targets were selected
and spiked into commercial CSF from healthy donors, digested and
analyzed by shotgun-MS to select peptides appropriate for the intended
analysis (Table 1). For the identified peptides (heavy and light), we
prioritized the following: (1) unique; (2) no missed cleavages (3) not
containing methionine; (4) no modifications; (5) detectable with the
highest intensity. Peptides were subsequently evaluated in terms of
giving reproducible signals between replicates and experiments to find
the optimum target representatives of the proteins of interest. Although
the shotgun-MS analysis of CSF served as a primary guide for peptide
selection, we included in the final PRM inclusion list of 17 proteins,
light and heavy peptides for the lower abundant proteins even when not
detectable in CSF from healthy donors (Supplementary Excel Tables 2
and 6).
Method development for the 17 targets for which QPrEST peptides
were detectable was performed in two steps.
Table 3
Method validation.
Calibration curve Precision Accuracy Carry-over



























Closeness (%) Light (%) Heavy (%)
ALDOC YTPEEIAMATVTALR – – – – – 5.52 31.1 30.8 0.88 ± 0.24 1.80 0.00 0.00
ALQASALNAWR 0.964 12.2 37.0 0.014 0.048 13.2 30.1 30.2 0.69 ± 0.20 4.01 0.00 0.00
DNAGAATEEFIK – – – – – 3.13 29.7 29.7 0.54 ± 0.14 0.84 0.00 0.00
APOA4 LAPLAEDVR 0.981 42.3 128 0.020 0.154 7.42 27.6 27.6 1.51 ± 0.37 6.84 0.00 0.00
ALVQQMEQLR 0.957 67.1 203 0.023 0.214 10.5 32.3 31.7 2.30 ± 0.66 11.3 0.00 0.00
VNSFFSTFK 0.975 48.6 147 0.063 0.220 13.1 23.4 21.5 2.20 ± 0.48 10.3 0.00 0.00
CCK AHLGALLAR – – – – – 38.5 47.5 32.2 0.03 ± 0.02 11.2 0.00 0.00
CKB FCTGLTQIETLFK – – – – – 19.3 34.3 35.6 0.01 ± 0.003 18.2 0.00 2.47
LGFSEVELVQMVVDGVK 0.926 0.305 0.924 0.0003 0.002 12.6 14.6 12.8 0.01 ± 0.001 2.84 0.00 2.23
GTGGVDTAAVGGVFDVSNADR – – – – – – – – – – – –
CTSD LLDIACWIHHK 0.931 174 529 0.125 0.607 24.9 30.4 21.2 15.4 ± 4.75 16.6 0.00 0.00
FDGILGMAYPR 0.973 148 450 0.191 0.543 10.5 15.9 14.5 8.79 ± 1.42 16.3 0.21 0.09
ISVNNVLPVFDNLMQQK 0.960 137 414 0.294 0.665 4.81 14.8 14.7 8.57 ± 1.14 14.3 0.00 0.00
LVDQNIFSFYLSR 0.986 80.2 243 0.070 0.260 5.85 12.9 12.6 7.53 ± 0.91 6.24 1.09 0.06
GAP43 GEGDAATEQAAPQAPASSEEK 0.905 1.79 5.41 0.006 0.009 11.9 31.2 32.8 0.02 ± 0.01 1.06 0.00 0.00
FGA PNNPDWGTFEEVSGNVSPGTR 0.931 156 472 0.008 0.018 11.4 24.1 23.7 5.92 ± 1.4 3.12 0.00 0.00
ITIH1 EVAFDLEIPK 0.980 6.49 19.7 0.009 0.014 3.76 29.0 29.0 0.52 ± 0.13 9.25 0.42 0.26
AAISGENAGLVR 0.984a 2.53 7.66 0.008 0.011 20.3 31.3 30.2 0.34 ± 0.11 11.2 0.00 0.00
LRG1 DLLLPQPDLR 0.982 20.0 60.7 0.006 0.018 4.25 19.5 19.4 1.05 ± 0.18 5.33 0.26 0.17
VAAGAFQGLR 0.933 32.8 99.3 0.016 0.037 11.5 33.2 33.5 1.90 ± 0.60 12.6 0.00 0.00
NBEA IHTTSDGMSSISER – – – – – – – – – – – –
GLEYAEMTATTLETESSSSK – – – – – – – – – – – –
NEFM EIEAEIQALR – – – – – – – – – – – –
VQSLQDEVAFLR – – – – – 22.5 23.4 19.7 – – 0.00 0.61
PLG WELCDIPR 0.963 228 692 0.150 0.320 4.22 41.4 41.5 10.8 ± 3.87 6.01 0.11 0.00
CTTPPPSSGPTYQCLK – – – – – 3.23 35.7 35.6 6.02 ± 1.83 3.16 0.00 0.00
PSAP LGPGMADICK 0.877 74.1 225 0.064 0.139 9.62 29.1 28.5 1.16 ± 0.30 16.5 0.00 0.00
EICALVGFCDEVK 0.889 9.92 30.1 0.004 0.017 – – – – – – –
NVIPALELVEPIK 0.964 3.30 9.99 0.007 0.010 6.39 15.2 14.3 0.15 ± 0.02 4.08 0.48 0.97
SDVYCEVCEFLVK 0.959 8.82 26.7 0.008 0.018 8.20 26.4 26.1 0.27 ± 0.06 11.1 2.00 1.67
EILDAFDK 0.926 54.2 164 0.031 0.089 8.98 26.9 25.7 0.97 ± 0.23 18.9 0.00 0.00
SERPINA1 LSITGTYDLK 0.986 798 2417 0.128 0.475 11.0 25.4 24.3 81.5 ± 19.0 16.5 0.09 0.11
SVLGQLGITK 0.958 1364 4132 0.319 0.902 5.32 28.5 28.2 66.1 ± 16.3 15.9 0.04 0.07
VFSNGADLSGVTEEAPLK 0.982 992 3005 0.143 0.569 11.0 27.7 26.7 74.1 ± 18.3 28.2 0.68 0.80
SERPINA3 AVLDVFEEGTEASAATAVK 0.979 264 800 0.097 0.235 9.79 19.2 16.6 25.3 ± 4.32 5.51 0.46 0.46
ITLLSALVETR 0.976 267 810 0.078 0.225 10.2 25.6 24.7 24.4 ± 5.62 4.47 0.14 0.26
SPARCL1 QEEDNTQSDDILEESDQPTQVSK 0.833 5.85 17.7 0.007 0.010 11.4 16.7 13.2 0.09 ± 0.01 10.6 0.00 0.37
TGLEAISNHK 0.948 31.9 96.6 0.009 0.027 17.3 42.7 41.9 0.38 ± 0.15 33.4 0.00 0.00
VCAM1 GIQVELYSFPR – – – – – 10.3 35.6 35.0 0.57 ± 0.18 3.50 0.00 0.00
a 8-point dilution curves from healthy pool, 10 μl CSF. Does not contain the two highest points.
b Inter-day precision CV calculated from replicate 1 on day 1–3, replicate 2 on day 1–3, replicate 3 on day 1–3, replicate 4 on day 1–3 [23]. “Method 1”.
c Inter-day precision CV calculated from the mean ratios collected on the different days 1–3. “Method 2”.
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In a first pilot study, we considered eight targets: ALDOC, CTSD,
FGA, GAP43, NEFM, PLG, SERPINA3 and VCAM1. For the analysis of
these proteins, we applied a traditional sample preparation for pro-
teomics involving ON trypsin digestion of 20 μl of CSF and peptide
clean-up by C18 ZipTip. Subsequently for the remaining nine targets we
decided to investigate the influence of experimental conditions in-
cluding digestion time, volume of CSF and peptide post digestion clean-
up procedure to obtain optimal recovery and assay performance for
most of the peptides.
To investigate the effect of digestion time, we allowed digestion to
proceed for 10, 30, 60, 180min and ON (16 h) and the resulting pep-
tides were analyzed by both shotgun-MS and PRM. Shotgun data ana-
lysis provided an overview of the digestion products, showing that the
number of missed cleavages per peptide was reduced with longer di-
gestions (Supplementary Fig. 1A). Even if, highly abundant proteins
showed fully digested peptides already after a short digestion time (≤
30min) (Supplementary Fig. 1B), when evaluating the consistency be-
tween replicates (difference in percentage < 25%, Supplementary
Fig. 1C), a clear improvement was found with ON digestion.
A selection of SPE cartridges with different sorbents was evaluated
for peptide clean-up. The highest number of identified peptides and
precision across all targets was found when using the neutral sorbent
HLB using a generic protocol (HLBg, 17 endogenous and 24 heavy;
HLBg; CV=3.38%, n=3) (Supplementary Fig. 1D, Supplementary
Excel Tables 1 and 3).
Peptide recovery repeatability and robustness of the analytical
method can increase increasing the amount of starting material ana-
lyzed. The use of 20 μL of CSF as the starting volume allowed for the
detection of expected low abundant peptides such as GEGDAATEQA-
APQAPASSEEK (GAP43) and LGFSEVELVQMVVDGVK (CKB)
(Supplementary Fig. 2A). Moreover, the precision was higher for most
of the peptides when starting from 20 μL of CSF (19 peptides, median
CV=9.5%) than from 10 μL of CSF (14 peptides, median CV =15.4%),
Supplementary Fig. 2B).
3.1.2. Validation of the methods
Based on the selected peptides and optimized parameters above, we
continued by assessing the performance of the PRM method by evalu-
ating linearity, LOQ, LOD, intra- and inter-day precision, accuracy and
carry-over. First, L/H peptide ratio of 1 was extrapolated from reverse
calibration curves constructed by a dilution series of the QPrESTs
spiked into a constant level of commercial CSF (data not shown). The
QPrESTs concentrations determined after spike-in by this experiment
are stated in Table 1.
The linearity, LOQ and LOD were estimated with a 12-point dilution
curve of the “high” pool (HLB clean-up) or commercial CSF (ZipTip
clean-up) prepared in artificial analyte-free CSF. Linearity, LOD and
LOQ were obtained for at least one peptide for each target protein
(Table 3), excluding the five low abundant proteins CCK, CKB, NBEA,
NEFM and VCAM1. These targets were detectable only in the high pool
but not in all its dilutions and could therefore not be evaluated in terms
of linearity. In summary, a validated method was developed for 13 out
of the 17 target proteins.
Results from the dilution series showed linear ranges of 2 to 5 orders
of magnitude depending on the target protein and specific peptides
with adjusted coefficients of determination (Adj R2) mean values of
0.945 (HLB method) and 0.964 (Ziptip method) (Fig. 2, Table 3 and
Supplementary Fig. 4).
Precision was assessed as intraday (within-day variability, 4 assays),
and interday repeatability (day-to-day variability, 3 days). Intraday
repeatability was generally below 25% (median CV=10.3%) with only
one peptide over 30% (AHLGALLAR, CCK). For this peptide, low re-
peatability was expected since the concentration appears to be close to
LOD. Inter-day repeatability calculated with method 2 (see Table 3)
ranged between 12.6% and 41.9% (median CV=26.7%). The peptides
TGLEAISNHK (SPARCL1) and WELCDIPR (PLG) had the highest inter-
day variation (41.9% and 41.5%, respectively) while all other measured
peptides showed variation between 12 and 33%. In conclusion, interday
precision was acceptable (CV<20%) for at least one peptide per pro-
tein and the values obtained with method 1 and method 2 were com-
parable (Table 3).
For those proteins where standard reference material for human
samples was not available, we estimated the accuracy using commercial
CSF and considered the mean concentration ± SD from all the samples
prepared (n=12) as the reference value. Then, the closeness to this
value was evaluated for one day of repeated experiments (n=4) and
accuracy ranged between 4.1% and 33%. Only the peptides VFSNGA-
DLSGVTEEAPLK (SERPINA1) and TGLEAISNHK (SPARCL1) showed
results> 20% and the rest of the peptides for those proteins had an
accuracy of 11–20% to the mean estimated concentration in CSF. Carry-
over (> 1%) was observed for 12 peptides (light and heavy) including
SDVYCEVCEFLVK (PSAP, light and heavy), FCTGLTQIETLFK (CKB,
heavy), LGFSEVELVQMVVDGVK (CKB, heavy) and LVDQNIFSFYLSR
(CTSD, heavy) which displayed maximum values of 2.5%. All measured
parameters describing the assay performance for each peptide are
summarized in Table 3.
3.2. Protein levels in CSF from AD patients and healthy controls
The PRM assays developed were further applied to profile and es-
timate concentrations of all 17 proteins detectable in CSF (13 validated
and 4 not fully validated methods) in 94 samples from both patients and
neurologically healthy controls (Table 2). Peptide levels obtained by
PRM were correlated with MFI data obtained by SBA analysis of the
same samples and also compared between patient groups. When com-
paring the orthogonal methods used to analyze the CSF samples,
Pearson correlations per protein between PRM (ratio L/H) and SBA
(MFI) measurement revealed correlation coefficients between 0.31 and
0.97 with strong (r > 0.60) or very strong (r > 0.80) concordance
between at least one peptide and antibody for GAP43, SERPINA3,
APOA4, LRG1, CCK and VCAM1 (Fig. 3, Supplementary Fig. 5, Table 4
and Supplementary Excel Table 4). For the group comparisons, differ-
ences in peptide levels between groups were statistically significant (p-
value< .05 after Bonferroni adjustment) for GAP43, VCAM1 CCK, CKB,
and PSAP. GAP43, VCAM1 and PSAP were found higher in AD and
preclinical samples with respect to non-AD MCI and controls (Fig. 4,
Table 4 and Supplementary Excel Table 5).
GAP43 had an estimated concentration range between 14 and
217 ng/mL. The PRM assay was based on one peptide (GEGDAATEQ-
AAPQAPASSEEK) with higher levels in AD and prodromal AD patients
(p≤ .01). Strong correlations were observed between the peptide and
antibody profiles obtained with HPA013392 (r=0.782) and
HPA013603 (r=0.764) while only a moderate correlation was ob-
served between the peptide and the third antibody HPA015600
(r=0.554). The antibody HPA015600 correlated moderately also with
the other two antibodies.
VCAM1 measurement was done using the peptide GIQVELYSFPR
and concentration was found particularly higher in preclinical samples
with respect to non-AD MCI and to the control group (p < .01), while
the difference was not statistically meaningful after Bonferroni cor-
rection between AD patients and control groups. PRM results showed
good correlation with one of the two anti-VCAM1 antibodies
Fig. 2. Selected peak identification and peptide linearity. Left: Chromatograms of PRM transitions. Right: Linearity plots from the peptide L/H ratio of the replicates
(n=3) with linear regression and 95% confidence interval. The x-axis shows the estimated concentration calculated by single point calibration based on the QPrEST
spike-in concentration.
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(HPA001618, r=0.723) and lower with the second antibody,
(HPA069867 r=0.551).
For PSAP, all the three peptides revealed concordant profiles be-
tween sample groups, but the peptide EILDAFDK provided the highest
statistical significance (p≤ .05). In this case, the same differences were
not observed by antibody profiling (HPA004426, HPA052900). The two
antibodies also showed poor correlation between each other.
For CCK and CKB, the differences between groups were statistically
significant only between the AD patients and control groups (CCK,
AHLGALLAR: AD vs. Control p-value= .02; CKB, LGFSEVELVQMVV-
DGVK: p-value= .009). The measurement of CKB performed with the
second peptide (GTGGVDTAAVGGVFDVSNADR) showed good corre-
lation (r=0.834) highlighting that the same trend between sample
groups was detected by the two peptides. Anyway the second peptide
did not show a statistically significant difference (GTGGVDTAAVGGV-
FDVSNADR, AD-control p-value= .31). In is important to acknowledge
that the quantitative method for GTGGVDTAAVGGVFDVSNADR was
not validated (Table 3), therefore the accuracy and precision may not
be good enough to detect correctly the differences between samples
groups, while the method based on the first peptide is more reliable.
LRG1 showed statistically increased levels in non-AD MCI compared to
the control group (DLLLPQPDLR: non-AD MCI-control p-value= .035).
Moreover, both peptides showed the same trend and there was a high
correlation between peptides and antibody (HPA001888) (r > 0.76).
All p-values obtained with and without correction and Pearson's coef-
ficients for all the correlation are listed in Table 4 and Supplementary
Excel Table 4.
Estimated concentration ranges based on the spiked in peptides for
the remaining proteins were: AHLGALLAR (CCK) 0.84–221 ng/mL,
GTGGVDTAAVGGVFDVSNADR (CKB) 0.87–24 ng/mL, LGFSEVELVQ-
MVVDGVK (CKB) 0.90–20 ng/mL, DLLLPQPDLR (LRG1) 126–2530 ng/
mL, VAAGAFQGLR (LRG1) 165–2954 ng/mL, EIEAEIQALR (NEFM)
0.10–12 ng/mL, EICALVGFCDEVK (PSAP) 61–250 ng/mL, EILDAFDK
(PSAP) 371–1757 ng/mL, SDVYCEVCEFLVK (PSAP) 95–516 ng/mL and
































































































































Fig. 3. Correlations between SBA and PRM measurement. Scatterplots and value of correlation (Pearson's r) between protein CSF levels measured by SBA (MFI value)
and PRM (L/H ratio).
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4. Discussion
The aim of our study was to develop and validate PRM assays to
perform an orthogonal verification of candidate biomarkers suggested
by antibody-based protein profiling [12]. MS owns a great potential as
an orthogonal method for validation of immunoassays data, featuring
unsurpassed specificity and high theoretical multiplexing capacity.
Nevertheless, a few aspects limit its application in respect to im-
munoassays: (i) the requirement of a laborious procedure for sample
preparation, which affects throughput and robustness; (ii) higher
sample consumption and (iii) lower sensitivity under the same condi-
tions of sample processing. Sensitivity comparable to immunoassays is
indeed achieved only upon protein/peptide pre-enrichment which im-
plies a longer sample processing. Here we described a simple and
straightforward analytical method that implies the digestion of un-de-
pleted CSF, the purification of peptides with SPE cartridges with broad
peptide affinity and the use of heavy labeled protein fragments as in-
ternal standards (QPrEST™). Starting from 20 targets of interest, 17
were detectable in CSF by PRM and analytical methods were developed
and validated for 13 of these candidates. The limit was mostly imposed
by the analytical sensitivity and by the lack of identification of pro-
teotypic peptides.
4.1. Analytical aspects of data verification by an orthogonal method
In scientific discussions about the challenges in biomarker discovery
and validation, there is general agreement that the quality of the ana-
lytical assays used for protein quantification is decisive for the success
of a biomarker's verification and later validation (as long as the bio-
marker has a robust association to the process it is thought to reflect,
which is a prerequisite). The extensive literature in analytical method
development shows that optimal experimental conditions are often
exquisitely peptide- and target-dependent. Therefore, an important
point in the process of implementing novel biomarkers reside in the
ability to translate a “proteomic assay”, which applies the same ex-
perimental conditions to analyze hundreds of targets, into a “target-
centric assay” passing gradually to a higher assay optimization. One of
our goals was to evaluate a method that could support the verification
of a large number of candidate biomarkers suggested by antibody-based
protein profiling. Evaluating basic experimental parameters such as
sample volume, time for digestion and SPE for purification, we con-
cluded that a good approach to have sensitivity in the range of medium
ng/ml included the use of ≥20 μL of CSF, ON digestion and HLB
(Waters) solid phase peptide purification (Supplementary Figs. 1 and
2).
Assay validation in proteomic studies is typically hampered by the
lack of standard references for the endogenous proteins. Indeed, even
when the heavy label standard for quantification is available, the lack
of endogenous protein references becomes the limiting factor. While it
would be expensive and time-consuming to produce light standard
protein for many dozens of analytes in the stage of verification, we
found the suggestion to pool samples from healthy and disease patients
(e.g. low and high pools) convenient (guidelines discussed during the
workshop about mass spectrometry based assays held the National
Institutes of Health in 2013) [21]. It is important to consider that low
numbers of samples to pool and small volumes can become a limiting
factor. In our case, the need for pooling many samples resulted in
protein dilution with consequent flattening of protein levels between
the pools (Supplementary Fig. 3). Therefore, we found it more con-
venient to generate a dilution curve of the high pool in artificial CSF.
While linearity can be satisfactorily determined using this approach for
the low range including LOQ and LOD, it becomes difficult to define the
upper limit of the linearity, which is limited by the highest con-
centration of the analytes in the high pool. Using the single point
standard approach, we obtained an estimated concentration for the
proteins in each sample that ranged from 1 ng/ml to 1mg/ml.
The correlations between PRM and SBA measurement for the targets










































































































































































































































































Fig. 4. Box-and-whisker plot visualization of protein profiles. Protein name and peptide are indicated on top of each plot. Left y-axis displays the peptide L/H ratio
and Right y-axis displays the estimated concentration. Red lines and asterisks indicate significant differences between two groups. (*) p-value< .01;(**) p-
value< .05. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Table 4). High correlations did not presuppose that the PrEST sequence
used to generate the HPA-antibodies was the same as the QPrEST. In-
deed, the highest peptide-antibody correlations were found when the
antibody and QPrEST targeted different regions of the protein of in-
terest (LRG1, GAP43, SERPINA3, Supplementary Excel Table 7).
There could be numerous reasons to why the results observed using
antibodies and PRM differ. Exposure of the epitope is crucial for anti-
body functionality and the location of the epitope in the secondary
structure could be the explanation as to why two antibodies to the same
protein show discordant results. In addition, the presence of different
proteoforms (isoform, fragments, and modifications) can typically lead
to the differential detectability of the same protein by a peptide and an
antibody., unless the assays are both developed to specifically targeted
to the modified form [33,34]. Low correlations between two antibody
measurements may also indicate off-target interactions while low
peptide-to-peptide correlation can be ascribed differences in digestion
or to the variable and unexpected modification.
4.2. CSF protein profiles associated with pre-clinical AD
In this study, we used PRM to verify the increased levels of GAP43
in CSF from early (preclinical-AD) and AD patients as previously ob-
served by Remnestål et al [12]. The pre-synaptic protein GAP43 is
central to neuronal development, axonal growth and plays an important
role in memory and information storage and altered levels of GAP43 in
CSF from AD and pre-clinical AD patients may reflect the synaptic de-
generation in the early onset of the disease. Interestingly, on tissue
level, expression of GAP-43 has been reported as lower in the frontal
cortex but not in the hippocampus [36]. Another interesting protein
that could be confirmed by PRM was VCAM1, a potential marker of
microvascular cerebral damage. High levels of VCAM1 in pre-clinical
AD patients would support the hypothesis that microvascular abnorm-
alities within the brain may precede neurodegeneration in AD [37].
Plasma VCAM1 levels moreover correlate with the gravity of dementia
in AD patients showing an association with white matter degradation
[38].
The PRM and SBA measurements of the two proteins PSAP and CKB
showed a poor or null correlation in our study. As mentioned above,
there could be both biological and technical reasons why the data ob-
tained using the two methods do not correlate. However, the strong
statistically significant difference observed between AD and preclinical
patients versus non-AD MCI and controls by PRM quantification high-
lights their possible role in the early phases of the disease.
PSAP (prosaposin) measurements were performed using three dif-
ferent peptides, all showing a similar trend. The peptide EILDAFDK
provided the highest statistical significance in group comparison and
good correlation with the second peptide SDVYCEVCEFLVK. The MS
data in this case confirm previous studies, where PSAP was found to be
significantly elevated in the CSF of AD and DLB but not in PD [14]. The
two antibodies (HPA004426 and HPA052900) poorly correlate with
each other and the lack of consistency between MS data and antibody-
based data could in this case potentially be due to differential detection
efficiency of the protein or alternatively events of cross-reactivity and
off-target binding. PSAP is the precursor of saposins and is secreted in
its full-length form into biological fluids such as CSF. PSAP is a neu-
rotrophic factor secreted in response to cellular stress, which mediates
pro-survival signaling pathways playing an important role in nerve
rescue regeneration [50].
CKB is involved in the regeneration of chemical energy, ATP, in the
brain. High consumptions of energy in the cells is associated with
higher levels of CKB expression [39], while lower activity of CKB has
been observed in neurodegenerative disorders such as AD and Pick's
disease [40] and ascribed to the oxidative damage and cellular stress
that occurs during AD and similar disorders [41].
CSF brain flow carries out several important functions including
distribution of neurotrophic factors and clearance of neurotoxic
products or solutes [35,36]. The high concentration of VCAM1, GAP43,
PSAP and CKB found in CSF of preclinical AD patients provide further
evidence to the involvement of cerebrovascular abnormalities [37],
inflammation [38], and synapsis failure [39] at the onset of AD. One
could also suggest that GAP43, VCAM1, PSAP and CKB might be pre-
sent at higher concentrations in AD CSF due to a lower CSF flow in AD.
However, the result that not all proteins are increased in a similar
manner argues against this interpretation.
4.3. CSF profiles associated to late-stage AD and non-AD MCI
CCK was found higher in AD compared to controls but not in pre-
clinical samples. This suggests that its presence in CSF may be more
related to the consequences of the later stages of disease. CCK is a
peptide hormone-synthetized from the 115-amino acid precursor, pre-
procholecystokinin which is further processed into pro-CCK (aa
21–115), and then into CCK-58, (aa 46–103) that can be cleaved to
form nine different peptides. While the two anti-CCK antibodies
(HPA045039, HPA069515) were raised against a sequence covering 9
out of 10 cholecystokinin peptides (aa 33–99, Supplementary Excel
Table 7), using PRM, we targeted the full form of CCK preprotein, or
specifically cholecystokinin-58 (CCK-58) (AHLGALLAR, aa 56–64, se-
quence not present in the other peptides). To best of our knowledge,
this is the first report suggesting altered levels of CCK-58 in CSF in the
context of AD, while decreased CSF concentrations of CCK-8 were found
in PD patients in other studies [45]. CCK mediates the satiety signal in
the peripheral digestive system, [46] and has a neuroprotective and
proliferative role, affecting memory and learning processes in the hip-
pocampus [42]. Interestingly while CCK levels physiologically increase
in CSF after eating [47], an association between overeating and hip-
pocampal impairment has been experimentally observed [43,44]. Little
is known about the role of CCK-58 in CSF of late stage AD patients, but
some elucidation might come in the future from studies about the
communication between the gastrointestinal tract and the hippocampus
through the vagus nerve [48]. LRG1 (Leucine-rich alpha-2-glycoprotein
1) levels correlated very well (Table 4), showing in agreement in-
creased levels of LRG1 in MCI but not in AD and control groups. Our
results are in line with those obtained by Miyajima et al. [45], where
high levels of LRG1 were found in CSF from patients affected by Par-
kinson's disease with dementia (PDD) and progressive supranuclear
palsy (PSP) but not in AD patients. LRG1 is known to be an in-
flammation-induced protein present at high levels in the CSF of ageing
humans [46] and altered levels CSF may reflect specific molecular
events involved in the onset of MCI and other neurodegenerative dis-
ease but not related specifically to the biological causes underpinning
AD development.
4.4. From verification to validation
Tissue leakage, altered clearance process [47] and variation in the
CSF flow are some of the known mechanism causing a change of protein
concentration in CSF. The latter has been hypothesized to be a cause
rather than a consequence of various forms of brain dysfunctions in-
cluding neurodegenerative disorders [48,49]. In order to better un-
derstand the biological meaning of the proteins discussed here and to
test their diagnostic value, further verification and validation studies
should involve the analysis of CSF samples from patients with other
neurodegenerative diseases such as PD and FTD, to assess similarities
and dissimilarities between the different pathologies and to evaluate
the specificity of the markers. Moreover in relation to the theory de-
scribed by Reiber et al. [49] about CSF flow and the anatomical
knowledge required to understand the meaning of variation in CSF
protein concentration, parallel studies of protein expression in brain
tissue should be performed.
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5. Conclusions
Our study demonstrated that the application of an orthogonal
method such as PRM for the verification of antibody-based experiments
is a convenient approach to confirm the most robust protein profiles
discovered. The comparison of data obtained by two different platforms
is a very powerful approach but the information gained should be in-
terpreted in the light of the fact that the two methods, based on dif-
ferent analytical principles, present peculiar limits in protein detection
and should be regarded as complementary.
The PRM assays presented here were validated for 13 target proteins
and can be useful in future for studies of larger sample cohorts. For the
low abundant targets for which it was not possible to evaluate the
linearity, it will be necessary to perform further analysis for method
validation including for example the use of protein standards or to
explore the possibilities of more sensitive assays such as im-
munocapture-MS or sandwich immunoassays.
The concordance between data obtained with two different
methods, supported by literature on their biological role, strongly
supports the analytical reliability of the markers identified associated to
the early onset of AD. To establish their potential as disease-associated
markers, further studies in independent sample collections are required.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.cca.2019.03.243.
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